Among the main factors involved in pathological angiogenesis in various chronic liver diseases [27], the authors highlighted the role of both VEGF and the placental growth factor (PlGF) on NASH progression as new targets for treating or preventing the disease [21]. The gene discussed is PGF; the disease is metabolic dysfunction-associated steatohepatitis.